The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
A new study shows that anal cancer, caused by the virus HPV, can be successfully fought in HIV-positive men by timely treatment and HPV vaccination of lesions that may ultimately lead to cancer.